z-logo
open-access-imgOpen Access
Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus–associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial
Author(s) -
Joseph N Jarvis,
Tshepo Leeme,
Mooketsi Molefi,
Awilly A Chofle,
Gabriella Bidwell,
Katlego Tsholo,
Nametso Tlhako,
Norah Mawoko,
Raju K K Patel,
Mark W. Tenforde,
Charles Muthoga,
Gregory P. Bisson,
Kidola Jeremiah,
John Changalucha,
David S. Lawrence,
Shabbar Jaffar,
William Hope,
Síle F. Molloy,
Thomas S. Harrison
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy515
Subject(s) - medicine , amphotericin b , confidence interval , cryptococcal meningitis , clinical endpoint , randomized controlled trial , fluconazole , meningitis , dose , human immunodeficiency virus (hiv) , gastroenterology , surgery , immunology , antifungal , viral disease , dermatology
We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom